SAN DIEGO, Dec. 14, 2016 /PRNewswire/ -- For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the 'Best New Drug' category at the Annual Scrip Awards.
Dr. Mireille Gillings presented HUYA Bioscience's Best New Drug Award to Sanofi Pasteur MSD, which was recognized for the launch of its new product, Dengvaxia (tetravalent dengue vaccine), a game-changing therapy for dengue fever. The award was presented at a ceremony at the Grosvenor House Hotel in London, UK, attended by over 500 industry leaders.
"Warmest congratulations to Sanofi Pasteur MSD on this well-deserved recognition of excellence," said Dr. Mireille Gillings, CEO and Executive Chair of HUYA. "As HUYA fully understands, finding new sources of innovation is an essential role of our industry, as we improve the health and quality of life of patients."
In the Best New Drug category, the judges sought the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represented the best therapeutic advance in its area. The recipient was selected by a 15-member, independent industry experts from around the world.
Since it was founded in 2004, HUYA has advanced the global development of novel oncology and cardiovascular drugs licensed from China. The company was the first to leverage the Tripartite Cooperation between China, Japan and South Korea to use clinical data from China to initiate drug development for HUYA's lead drug HBI-8000 in Japan for lymphoma. HBI-8000 is also advancing in several solid tumor indications in the U.S. HUYA's drug has immunomodulatory properties which are important to the clinical development of immuno-oncology therapeutics.
About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations have been established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. With the largest team of scientists working with Chinese innovators, HUYA develops promising drug candidates globally. For more information, please visit www.huyabio.com
About the SCRIP Awards
The SCRIP Awards provide the industry with an opportunity to acknowledge and applaud its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement. For details, please visit www.scripawards.com
HUYA Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/huya-bioscience-international-sponsors-12th-annual-scrip-awards-best-new-drug-category-300377949.html
SOURCE HUYA Bioscience International